Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis

Eitemau Tebyg

• Comparing the long‐term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease‐modifying antirheumatic drug in patients with inflammatory polyarthritis
  gan: Hider, S L, et al.
  Cyhoeddwyd: (2006)
• Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis
  gan: Franklin, Jarrod, et al.
  Cyhoeddwyd: (2010)
• In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register
  gan: Verstappen, Suzanne M M, et al.
  Cyhoeddwyd: (2011)
• Early functional disability predicts both all‐cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register
  gan: Farragher, Tracey M, et al.
  Cyhoeddwyd: (2007)
• Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies
  gan: Farragher, Tracey M, et al.
  Cyhoeddwyd: (2010)